Dexibuprofen for fever in children with upper respiratory tract infection

Kim, Chang Keun; Callaway, Zak; Choung, Ji Tae; Yu, Jihion; Shim, Kye Shik; Kwon, Eun Mi; Koh, Young Yull

doi:10.1111/ped.12125

Cited by 11 publications

(13 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 and Table 4 ). We also found that genes in the network, such as PTGS2 and PTGS1, are targeted by a variety of nonsteroidal anti-inflammatory drugs (NSAIDs), including dexibuprofen, mefenamic acid, and bufexamac to improve symptoms of fever, rash, and insomnia 67 – 69 . It is similar and biomedical meaningful for the other 4 insomnia-related symptom clusters.…”

Section: Resultsmentioning

confidence: 96%

“…In our study, most of the symptoms with gene associations belong to the nervous system, which would be result in certain deviations. However, the 341 symptoms in our work have covered 180 (46.63%) of symptoms in Medical Subject Heading vocabulary 67 which was created and updated annually by the NLM since 1960s. This means that our results would deliver some kinds of reliable and useful knowledge for understanding the network mechanisms of the whole spectrum of symptom phenotypes.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Diversity and molecular network patterns of symptom phenotypes

et al. 2021

View full text Add to dashboard Cite

Symptom phenotypes have continuously been an important clinical entity for clinical diagnosis and management. However, non-specificity of symptom phenotypes for clinical diagnosis is one of the major challenges that need be addressed to advance symptom science and precision health. Network medicine has delivered a successful approach for understanding the underlying mechanisms of complex disease phenotypes, which will also be a useful tool for symptom science. Here, we extracted symptom co-occurrences from clinical textbooks to construct phenotype network of symptoms with clinical co-occurrence and incorporated high-quality symptom-gene associations and protein–protein interactions to explore the molecular network patterns of symptom phenotypes. Furthermore, we adopted established network diversity measure in network medicine to quantify both the phenotypic diversity (i.e., non-specificity) and molecular diversity of symptom phenotypes. The results showed that the clinical diversity of symptom phenotypes could partially be explained by their underlying molecular network diversity (PCC = 0.49, P-value = 2.14E-08). For example, non-specific symptoms, such as chill, vomiting, and amnesia, have both high phenotypic and molecular network diversities. Moreover, we further validated and confirmed the approach of symptom clusters to reduce the non-specificity of symptom phenotypes. Network diversity proposes a useful approach to evaluate the non-specificity of symptom phenotypes and would help elucidate the underlying molecular network mechanisms of symptom phenotypes and thus promotes the advance of symptom science for precision health.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Diversity and molecular network patterns of symptom phenotypes

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Tables 2 and 3 present the results of each of these studies. 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 …”

Section: Resultsmentioning

confidence: 99%

Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: An updated systematic review

Azh

Barzkar

Motamed-Gorji

et al. 2022

Pharmacology Res & Perspec

View full text Add to dashboard Cite

In this systematic review, we aimed to assess the efficacy and safety of nonsteroidal anti‐inflammatory drugs (NSAIDs) in treating respiratory tract infections in adults and children. PubMed, Scopus, Web of Science, Cochrane, and Embase databases were searched. A total of 34 randomized clinical trials were included in this systematic review. We assessed the risk of bias of all included studies using the Cochrane tool for risk of bias assessment. The evidence on ibuprofen, naproxen, aspirin, diclofenac, and other NSAIDs were rated for degree of uncertainty for each of the study outcomes and summarized using the grading of recommendations assessment, development, and evaluation (GRADE) approach. Our findings suggest that high‐quality evidence supports the use of NSAIDs to reduce fever in both adults and children. However, the evidence was uncertain for the use of NSAIDs to reduce cough. Most studies showed that NSAIDs significantly relieved sore throat. The evidence for mortality and oxygenation is limited. Regarding the adverse events, gastrointestinal discomfort was more frequently reported in children. For adults, our overall certainty in effect estimates was low and the increase in gastrointestinal adverse events was not clinically significant. In conclusion, NSAIDs seem to be beneficial in the outpatient management of fever and sore throat in adults and children. Although the evidence does not support their use to decrease mortality nor improve oxygenation in inpatient settings, the use of NSAIDs did not increase the rate of death or the need for ventilation in patients with respiratory tract infections. Further studies with a robust methodology and larger sample sizes are recommended.

show abstract

“…Dexibuprofen and acetaminophen are the two most widely used antipyretic drugs in the pediatric population. The former is an enantiomer of racemic ibuprofen, an effective and tolerable antipyretic and analgesic drug for pediatric use [ 12 – 14 ], and an equal effect at a lower dose than ibuprofen has been shown in previous studies [ 15 – 17 ], some including pediatric upper respiratory tract infection (URTI) patients presenting with fever [ 18 , 19 ]. Acetaminophen is another popular choice of pediatric antipyretic drug, which is generally administered via oral route.…”

Section: Discussionmentioning

confidence: 99%

The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial

et al. 2018

View full text Add to dashboard Cite

BackgroundWe aimed to compare the antipyretic efficacy, safety, and tolerability between oral dexibuprofen and intravenous propacetamol in children with upper respiratory tract infection (URTI) presenting with fever.MethodsPatients aging from 6 months to 14 years admitted for URTI with axillary body temperature ≥ 38.0 °C were enrolled and randomized into the study or control group. Patients in the study group were intravenously infused with propacetamol and subsequently oral placebo medication was administered. Patients in the control group were intravenously infused with 100 mL of 0.9% sodium chloride solution without propacetamol and then oral dexibuprofen was administered. We checked the body temperature of all patients at 0.5 h (hr), 1 h, 1.5 h, 2 h, 3 h, 4 h, and 6 h after oral placebo or dexibuprofen had been applied.ResultsA total of 263 patients (125 in the study group) were finally enrolled. The body temperatures of patients in the study group were significantly lower until 2 h after administration (37.73 ± 0.58 vs 38.36 ± 0.69 °C (p < 0.001), 37.37 ± 0.53 vs 37.88 ± 0.69 °C (p < 0.001), 37.27 ± 0.60 vs 37.62 ± 0.66 °C (p < 0.001), 37.25 ± 0.62 vs 37.40 ± 0.60 °C (p = 0.0452), at 0.5 h, 1 h, 1.5 h, and 2 h, respectively). The two groups showed no significant differences in terms of the range of body temperature decrease, the Area Under the Curve of body temperature change for antipyretic administration-and-time relationship, the maximum value of body temperature decrease during the 6 h test period, the number of patients whose body temperature normalized (< 37.0 °C), the mean time when first normalization of body temperature, and the development of adverse events including gastrointestinal problem, elevated liver enzyme, and thrombocytopenia.ConclusionsIntravenous propacetamol may be a safe and effective choice for pediatric URTI patients presenting with fever who are not able to take oral medications or need faster fever control.Trial registrationCRIS KCT0002888. Date of registration: July 31st, 2013.

show abstract

Dexibuprofen for fever in children with upper respiratory tract infection

Abstract: Dexibuprofen (3.5 or 7 mg/kg) is as effective and tolerable as ibuprofen for fever caused by upper respiratory tract infection in children.

Cited by 11 publications

References 23 publications

Diversity and molecular network patterns of symptom phenotypes

Diversity and molecular network patterns of symptom phenotypes

Nonsteroidal anti‐inflammatory drugs in acute viral respiratory tract infections: An updated systematic review

The antipyretic efficacy and safety of propacetamol compared with dexibuprofen in febrile children: a multicenter, randomized, double-blind, comparative, phase 3 clinical trial

Contact Info

Product

Resources

About